Amgen Inc.
Erenumab compositions and uses thereof

Last updated:

Abstract:

The present invention relates to compositions comprising erenumab and one or more erenumab variants, including isomerization variants, deamidation variants, acidic variants, and HMW species. Pharmaceutical formulations comprising the erenumab compositions and methods of using and characterizing the compositions are also described.

Status:
Grant
Type:

Utility

Filling date:

1 Apr 2019

Issue date:

9 Aug 2022